Table 1

Clinical characteristics of the study group participants

OverallControl subjectsAAB FDRAAB+ singleAAB+ multipleRecent onset
N (%)22949 (21.4)61 (26.6)31 (13.5)36 (15.7)52 (22.7)
Male sex101 (44.1)20 (40.8)23 (37.7)9 (29.0)22 (61.1)27 (51.9)
Age (years)19.6 ± 10.518.4 ± 5.921.1 ± 11.728.8 ± 13.315.9 ± 10.716.2 ± 6.1
Body weight (kg)61.0 ± 23.761.8 ± 17.863.0 ± 22.175.3 ± 31.049.9 ± 22.661.3 ± 23.0
BMI23.2 ± 6.422.7 ± 4.823.6 ± 6.127.6 ± 8.620.0 ± 5.722.6 ± 5.9
PV74.9 ± 31.888.2 ± 30.881.2 ± 29.889.3 ± 35.461.2 ± 28.055.7 ± 21.6
RPVBW1.2 ± 0.41.4 ± 0.41.3 ± 0.31.2 ± 0.31.2 ± 0.20.9 ± 0.2
RPVBMI3.2 ± 1.13.9 ± 1.13.5 ± 0.93.3 ± 1.13.0 ± 1.02.5 ± 0.2
RPV-to-height ratio0.5 ± 0.20.5 ± 0.20.5 ± 0.20.5 ± 0.20.4 ± 0.10.3 ± 0.1
Race/ethnicity
 NH white177 (77.3)28 (57.1)52 (85.3)25 (80.7)29 (80.6)43 (82.7)
 NH black11 (4.8)5 (10.2)1 (3.2)3 (8.3)2 (3.9)
 NH Asian2 (0.9)1 (2.0)1 (1.9)
 NH Am. Indian, Alaska Native
 NH Hawaiian, Pacific Islander1 (0.4)1 (2.0)
 Hispanic27 (11.8)6 (12.2)8 (13.1)4 (12.9)4 (11.1)5 (9.6)
 NH multiple race/unknown11 (4.8)8 (16.3)1 (1.6)1 (3.2)1 (1.9)
Laboratory tests*
 HbA1c (%)5.5 ± 1.05.0 ± 0.35.1 ± 0.35.2 ± 0.35.1 ± 0.47.0 ± 1.3
 HbA1c (mmol/mol)36.8 ± 11.231.5 ± 3.632.0 ± 3.333.5 ± 3.532.6 ± 3.952.6 ± 13.9
 Glucose (mg/dL)104.0 ± 37.590.0 ± 6.093.0 ± 6.796.0 ± 8.794.7 ± 16.0141.4 ± 64.3
 C-peptide (ng/mL)2.0 ± 1.22.1 ± 0.72.3 ± 1.32.5 ± 1.21.9 ± 1.21.2 ± 0.9
 Trypsinogen (ng/mL)23.9 ± 18.923.4 ± 10.025.8 ± 12.438.2 ± 40.520.0 ± 8.616.3 ± 9.9
  • Data are mean ± SD or N (%). Am. Indian, American Indian; NH, non-Hispanic.

  • *HbA1c (% and mmol/mol), n missing = 5; glucose, n missing = 0; C-peptide, n missing = 1; trypsinogen, exclusion of outlier n = 1 and missing for analysis = 16.